oru.sePublications
Change search
Link to record
Permanent link

Direct link
BETA
Publications (6 of 6) Show all publications
Löwa, A., Jevtic, M., Gorreja, F. & Hedtrich, S. (2018). Alternatives to animal testing in basic and preclinical research of atopic dermatitis. Experimental dermatology, 27(5), 476-483
Open this publication in new window or tab >>Alternatives to animal testing in basic and preclinical research of atopic dermatitis
2018 (English)In: Experimental dermatology, ISSN 0906-6705, E-ISSN 1600-0625, Vol. 27, no 5, p. 476-483Article, review/survey (Refereed) Published
Abstract [en]

Atopic dermatitis (AD) is a chronic inflammatory skin disease of increasing prevalence, especially in industrialized countries. Roughly 25% of the children and 1%-3% of adults are affected. Although significant progress has been made in the understanding of the pathogenesis of AD, many aspects remain poorly understood. Moreover, there is a pressing need for improved therapeutic options. Studies to elucidate the pathophysiological pathways of AD and to identify novel therapeutic targets over the last few decades have been conducted almost exclusively in animal models. However, in vitro approaches such as 3D skin disease models have recently emerged due to an increasing awareness of distinct interspecies-related differences that hamper the effective translation of results from animal models to humans. In addition, there is growing political and social pressure to develop alternatives to animal models according to the 3Rs principle (reduction, refinement and replacement of animal models).

Place, publisher, year, edition, pages
Wiley-Blackwell Publishing Inc., 2018
Keywords
3R approach, atopic dermatitis, preclinical dermatology, skin equivalents, skin model
National Category
Dermatology and Venereal Diseases
Identifiers
urn:nbn:se:oru:diva-64718 (URN)10.1111/exd.13498 (DOI)000434355700009 ()29356091 (PubMedID)2-s2.0-85042111814 (Scopus ID)
Note

Funding Agency:

Berlin Brandenburg 3R Research Platform

Available from: 2018-02-01 Created: 2018-02-01 Last updated: 2019-03-25Bibliographically approved
Gorreja, F., Rush, S., Kasper, D., Brummer, R. J., Meng, D. & Walker, W. A. (2018). Beneficial bacteria that affect Toll-like receptors in the gut immune system: the case of PSA on Bacteroides fragilis and transcription profile of developmentally-regulated genes. In: : . Paper presented at Nobel Day, 10th Conference, School of Medical Sceinces, Örebro University, 10 December, 2018.
Open this publication in new window or tab >>Beneficial bacteria that affect Toll-like receptors in the gut immune system: the case of PSA on Bacteroides fragilis and transcription profile of developmentally-regulated genes
Show others...
2018 (English)Conference paper, Poster (with or without abstract) (Other academic)
National Category
Medical and Health Sciences Immunology
Identifiers
urn:nbn:se:oru:diva-70701 (URN)
Conference
Nobel Day, 10th Conference, School of Medical Sceinces, Örebro University, 10 December, 2018
Available from: 2018-12-11 Created: 2018-12-11 Last updated: 2018-12-17Bibliographically approved
Gorreja, F., Rangel, I., Rush, S., Wall, R., De Vos, W. M. & Brummer, R. J. (2018). Double-blind cross-over trial reveals human mucosal transcriptome responses to variants of LGG administration in vivo. In: Peter Konturek (Ed.), Targeting microbiota: 6th World congress on targeting microbiota towards clinical revolution. Paper presented at 6th World Congress on Targeting Microbiota, Porto, Portugal, October 28-30, 2018. Porto, Portugal: ISM, 5, Article ID 978-2-35609-010-2.
Open this publication in new window or tab >>Double-blind cross-over trial reveals human mucosal transcriptome responses to variants of LGG administration in vivo
Show others...
2018 (English)In: Targeting microbiota: 6th World congress on targeting microbiota towards clinical revolution / [ed] Peter Konturek, Porto, Portugal: ISM , 2018, Vol. 5, article id 978-2-35609-010-2Conference paper, Poster (with or without abstract) (Other academic)
Place, publisher, year, edition, pages
Porto, Portugal: ISM, 2018
Series
Archives of international society of microbiota, ISSN 978-2-35609-010-2
National Category
Medical and Health Sciences Genetics
Identifiers
urn:nbn:se:oru:diva-69884 (URN)
Conference
6th World Congress on Targeting Microbiota, Porto, Portugal, October 28-30, 2018
Available from: 2018-10-28 Created: 2018-10-28 Last updated: 2018-11-12Bibliographically approved
Gorreja, F., Rush, S., Marques, T. M., Repsilber, D., Baker, A., Wall, R. & Brummer, R. J. (2018). The impacts of probiotics and prebiotics on the gut mucosa and immune system through targeting inflammation and intestinal barrier function. In: : . Paper presented at Food and Inflammation - 2nd Conference of Food Science Sweden, Örebro, Sweden, 21 Nov., 2018.
Open this publication in new window or tab >>The impacts of probiotics and prebiotics on the gut mucosa and immune system through targeting inflammation and intestinal barrier function
Show others...
2018 (English)Conference paper, Oral presentation only (Other academic)
Keywords
Probiotics, Inflammation, Prebiotics, Immune system, Dietary
National Category
Medical and Health Sciences Microbiology
Research subject
Molecular Biology; Medicine; Microbiology
Identifiers
urn:nbn:se:oru:diva-70257 (URN)
Conference
Food and Inflammation - 2nd Conference of Food Science Sweden, Örebro, Sweden, 21 Nov., 2018
Available from: 2018-11-21 Created: 2018-11-21 Last updated: 2019-04-24Bibliographically approved
Gorreja, F., Damuzzo, V., Gallo, U., Russi, A., Lo Re, F., Ciampalini, S., . . . Palozzo, C. (2017). A survey on patients medication reconciliation process in an oncological hospital. Recenti Progressi in Medicina, 108(3), 141-148
Open this publication in new window or tab >>A survey on patients medication reconciliation process in an oncological hospital
Show others...
2017 (English)In: Recenti Progressi in Medicina, ISSN 0034-1193, Vol. 108, no 3, p. 141-148Article in journal (Other academic) Published
Abstract [en]

Objectives. The purpose of this study was to assess the impact of medication reconciliation in the clinical practice from a hospital pharmacist point of view.

Methods. A survey of the medication taken by cancer patients was performed on admission and on discharge in an Oncological hospital, and then the subjects were followed up until discharge for 8 weeks. The pharmacist entered the data collected into a computer based tool which, by using Screening Tool of Older Persons’ Potentially Inappropriate Prescriptions (STOPP criteria) and Micromedex™ interactions database, automatically produces a report indicating the possible inconsistencies. The report is to check all potentially inappropriate prescriptions (PIPs) correlated to the drugs assumption by the patient. The appropriateness of the medication was scored using a Medication Appropriateness Index (MAI index) which was used to reconcile the medication list accordingly.

Results. Patients reconciled at admission were 98, while patients reconciled at discharge were 90, 8 patients dropped out due to death. After the intervention of the hospital pharmacist, the average value of MAI index showed a significant reduction (3,391 to 2,552 p=0.039) and the median number of drugs prescribed per patient was decreased (7 vs 6; p=0.8058).

Conclusion. Our study demonstrated that the forms used in the reconciliation process, in particular the record card, is a promising method to increase the quality of the information related to drug use in clinical decisions. We think that medication reconciliation softwares should be widely used by health care professionals involved in the recording of drug history or prescription process.

Place, publisher, year, edition, pages
Rome, Italy: Il Pensiero Scientifico Editore, 2017
Keywords
Drug interactions, Medication Appropriateness Index, medication reconciliation, oncology, patients safety, potentially inappropriate prescriptions
National Category
Medical and Health Sciences Pharmacology and Toxicology
Research subject
Pharmaceutical Pharmacology
Identifiers
urn:nbn:se:oru:diva-65206 (URN)10.1701/2656.27237 (DOI)28398408 (PubMedID)2-s2.0-85021124174 (Scopus ID)
Note

Note: The name of "IRCCS" or technically “Istituto di Ricovero e Cura a Carattere Scientifico” indicates biomedical institutions of relevant national interest, which drive clinical assistance in strong relation to research activities.

Available from: 2018-02-24 Created: 2018-02-24 Last updated: 2019-03-25Bibliographically approved
Russi, A., Damuzzo, V., Serena, M., Gorreja, F. & Palozzo, A. C. (2016). Improving the management of high cost anticancer drugs in a health care system. Global and Regional Health Technology Assessment, 3(3), 155-158
Open this publication in new window or tab >>Improving the management of high cost anticancer drugs in a health care system
Show others...
2016 (English)In: Global and Regional Health Technology Assessment, ISSN 2284-2403, Vol. 3, no 3, p. 155-158Article in journal (Other academic) Published
Abstract [en]

As a consequence of the rise in cancer prevalence and in the cost of anticancer drugs, global spending for cancer is increasing rapidly. The aim of this work is to identify and assess some effective cost management parameters and possible strategies to contain expenditure. Cost limitation could be achieved by implementing effective prevention measures and other main actions: diffusion of tailored therapies; systematic postmarketing reviews; cost-effectiveness assessment; accurate treatment choices; more transparent and effective managed entry agreement policies; waste management through personalized dose preparation. To better manage high cost anticancer drugs, oncologists and hospital pharmacists should collaborate in choosing the right drug, for the right patient, at the right time. In addition, besides promoting the use of biosimilars and generic drugs, when different products have a similar clinical effectiveness, a cost-minimization analysis should be performed to identify the best clinical approach at the lowest cost. With the same purpose, verifying real life outcomes by managing postmarketing analyses helps to renegotiate price agreements in a value-for-money model; this could be arranged if the regulatory agencies renegotiate the previously established price within a defined time period. Finally, the centralization of high-cost drug preparation and the implementation of a drug-day (vial sharing) will reduce drug waste.

Place, publisher, year, edition, pages
Milan, Italy: Wichtig Publishing, 2016
Keywords
Drug expenditure, managed entry agreement, oncology, preparation waste, postmarketing register
National Category
Medical and Health Sciences Health Care Service and Management, Health Policy and Services and Health Economy
Research subject
Health and Medical Care Research; Economics
Identifiers
urn:nbn:se:oru:diva-65210 (URN)10.5301/grhta.5000243 (DOI)000405311400006 ()
Available from: 2018-02-24 Created: 2018-02-24 Last updated: 2019-03-25Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0003-3548-4618

Search in DiVA

Show all publications